
Quarterly report 2025-Q2
added 08-04-2025
Glaukos Corporation Cash Flow 2011-2026 | GKOS
Annual Cash Flow Glaukos Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-57.8 M | -33.1 M | 24.7 M | -23 M | -369 K | 18.9 M | 26.1 M | 12.3 M | -2.19 M | - | - | - | - |
Depreciation & Amortization |
33.7 M | 31.6 M | 29.7 M | 29.4 M | 6.31 M | 6.26 M | 5.48 M | 4.72 M | 4.27 M | 4.23 M | 1.16 M | - | - |
Accounts Payables |
13.4 M | 14.4 M | 7.33 M | 4.37 M | 5.78 M | 6.29 M | 6.24 M | 2.97 M | 3.63 M | - | - | - | - |
Accounts Receivables |
39.8 M | 36.1 M | 33.4 M | 36.1 M | 38.4 M | 18.7 M | 16.7 M | 14.3 M | 7.55 M | - | - | - | - |
Total Inventories |
42 M | 37.8 M | 23 M | 15.8 M | 42.6 M | 13.3 M | 11.2 M | 6.84 M | 4.1 M | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Glaukos Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -18.5 M | - | - | -33.9 M | - | - | - | -30.8 M | - | - | - | 9.77 M | - | - | - | 4.18 M | - | -33.6 M | -24 M | -13.1 M | - | 3.82 M | 6.81 M | 208 K | - | 1.74 M | -2.63 M | -6.45 M | - | 13.6 M | 6.64 M | 2.33 M | - | 9.03 M | 5.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
- | 8.23 M | - | - | 8.91 M | - | - | - | 2.08 M | - | - | - | 1.38 M | - | - | - | 1.15 M | - | 3.3 M | 2.19 M | 1.08 M | - | 2.67 M | 1.73 M | 842 K | - | 5.06 M | 3.36 M | 1.66 M | - | 3.94 M | 2.43 M | 1.01 M | - | 3.41 M | 2.26 M | 1.12 M | - | 3.2 M | 2.14 M | 1.07 M | - | 3.16 M | 2.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
13.7 M | 15.8 M | 13 M | 11.6 M | - | 13.4 M | 10.4 M | 8.56 M | 12 M | 14.4 M | - | - | 8 M | 7.33 M | 8.46 M | 6.96 M | 8.62 M | 4.37 M | 4.37 M | 4.37 M | 4.37 M | 5.78 M | 5.78 M | 5.78 M | 5.78 M | 6.29 M | 6.29 M | 6.29 M | 6.29 M | 6.24 M | 6.24 M | 6.24 M | 6.24 M | 2.97 M | 2.97 M | 2.97 M | 2.97 M | 3.63 M | 3.63 M | 3.63 M | 3.63 M | 3.3 M | 3.3 M | 3.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
83 M | 71.5 M | 60.7 M | 51.2 M | - | 39.8 M | 39.3 M | 39.3 M | 37.9 M | 36.1 M | - | - | 34.8 M | 33.4 M | 35.2 M | 37.6 M | 36.7 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 7.55 M | 7.55 M | 7.55 M | 7.55 M | 5.4 M | 5.4 M | 5.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
64.6 M | 59.5 M | 57.7 M | 56.5 M | - | 42 M | 39.8 M | 39.4 M | 40.5 M | 37.8 M | - | - | 24.7 M | 23 M | 19.7 M | 17.5 M | 15.3 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 6.84 M | 6.84 M | 6.84 M | 6.84 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 2.26 M | 2.26 M | 2.26 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Glaukos Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
iRhythm Technologies
IRTC
|
$ 122.35 | 0.73 % | $ 3.92 B | ||
|
Alcon
ALC
|
$ 75.8 | -0.08 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
$ 3.96 | -0.75 % | $ 183 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 10.99 | 1.48 % | $ 26.7 M | ||
|
The Cooper Companies
COO
|
$ 64.42 | -0.82 % | $ 12.8 B | ||
|
Haemonetics Corporation
HAE
|
$ 59.93 | 0.52 % | $ 3.02 B | ||
|
electroCore
ECOR
|
$ 6.18 | -0.08 % | $ 52.4 K | ||
|
ICU Medical
ICUI
|
$ 124.82 | 0.22 % | $ 3.08 B | ||
|
Envista Holdings Corporation
NVST
|
$ 26.8 | -0.89 % | $ 4.5 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
$ 482.22 | 0.71 % | $ 172 B | ||
|
Pulse Biosciences
PLSE
|
$ 23.02 | -5.07 % | $ 1.55 B | ||
|
Microbot Medical
MBOT
|
$ 2.2 | 0.92 % | $ 101 M | ||
|
STAAR Surgical Company
STAA
|
$ 25.67 | 3.34 % | $ 1.27 B | ||
|
STERIS plc
STE
|
$ 221.8 | -0.77 % | $ 21.9 B | ||
|
Masimo Corporation
MASI
|
$ 178.63 | -0.04 % | $ 9.52 B | ||
|
Milestone Scientific
MLSS
|
$ 0.32 | -1.27 % | $ 26.3 M | ||
|
InfuSystem Holdings
INFU
|
$ 10.34 | 0.68 % | $ 214 M | ||
|
Stereotaxis
STXS
|
$ 1.93 | -1.53 % | $ 176 M | ||
|
Merit Medical Systems
MMSI
|
$ 68.58 | -0.04 % | $ 4.06 B | ||
|
Teleflex Incorporated
TFX
|
$ 136.56 | -0.07 % | $ 6.09 B | ||
|
Utah Medical Products
UTMD
|
$ 67.17 | -1.03 % | $ 218 M | ||
|
West Pharmaceutical Services
WST
|
$ 306.16 | -1.14 % | $ 22.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.91 | 0.08 % | $ 2.37 B | ||
|
Retractable Technologies
RVP
|
$ 0.65 | 0.2 % | $ 19.5 M | ||
|
Pro-Dex
PDEX
|
$ 52.1 | 2.24 % | $ 171 M | ||
|
LeMaitre Vascular
LMAT
|
$ 113.45 | 0.49 % | $ 2.57 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
$ 21.38 | -1.57 % | $ 985 M | ||
|
Baxter International
BAX
|
$ 18.16 | -1.39 % | $ 9.32 B | ||
|
ResMed
RMD
|
$ 219.85 | 0.15 % | $ 32.1 B | ||
|
AtriCure
ATRC
|
$ 29.28 | 3.79 % | $ 1.4 B | ||
|
Harvard Bioscience
HBIO
|
$ 6.86 | 1.18 % | $ 305 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
$ 11.1 | -0.89 % | $ 453 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 152.14 | -1.74 % | $ 43.8 B | ||
|
Nephros
NEPH
|
$ 2.87 | 1.06 % | $ 29.8 M | ||
|
OraSure Technologies
OSUR
|
$ 3.0 | -1.64 % | $ 220 M | ||
|
Repligen Corporation
RGEN
|
$ 117.6 | 3.1 % | $ 6.55 M |